Company news
Outlook Therapeutics, Inc. news in 2020
Outlook Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update
December 22, 2020
Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
November 30, 2020
Outlook Therapeutics Announces Creation of Global Retina Advisory Council
November 18, 2020
Outlook Therapeutics Secures $10 Million in Additional Working Capital
November 4, 2020
Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
November 2, 2020
Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
October 12, 2020
Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration
September 29, 2020
Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) from NORSE 1
August 25, 2020
Outlook Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2020 and Provides Corporate Update
August 13, 2020
Outlook Therapeutics Announces Closing of $1.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
July 16, 2020
Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
July 6, 2020
Outlook Therapeutics Announces Closing of $10.2 Million Financing Priced At-The-Market Under Nasdaq Rules
June 24, 2020
Outlook Therapeutics Announces $11.2 Million Financings Priced At-The-Market Under Nasdaq Rules
June 22, 2020
Outlook Therapeutics Provides Clinical Update on ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
June 16, 2020
Outlook Therapeutics Announces Closing of $16.0 Million Private Placement
June 2, 2020
Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
May 25, 2020
Outlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate Update
May 14, 2020
Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors
April 20, 2020
Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2
April 13, 2020
Outlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved
March 4, 2020
Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market
February 25, 2020
Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market
February 23, 2020
Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020
February 13, 2020
Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010
January 27, 2020